Product Information
AMITRIPTYLINE HCL 150 MG TAB is a generic product labeled by Advagen Pharma Ltd., priced at $0.2899 per EA under NDC 72888007201. Its NADAC has been published 82 times since Mar 12, 2025.
FDA first approved this application on May 1, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888007201
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMITRIPTYLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215376FDA Approved
5/1/2023
TE Code
AB
On Market Since
5/1/2023
Pharmacological Classes
Price Statistics
The NADAC for AMITRIPTYLINE HCL 150 MG TAB has been published 82 times since Mar 12, 2025, and over the history we have for it it has risen 56.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2899 per EA |
|---|---|
| All-time high | $0.3070 (Sep 16, 2026) |
| All-time low | $0.1849 (Mar 19, 2025) |
| 52-week high | $0.3070 |
| 52-week low | $0.2620 |
| Median price | $0.2831 |
| Average price | $0.2579 |
| Largest weekly change | +17.9% (Sep 17, 2025) |
| Weeks tracked | 82 |
| Tracking since | Mar 12, 2025 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amitriptyline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMITRIPTYLINE HCL 150 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for AMITRIPTYLINE HCL 150 MG TAB, manufactured by Advagen Pharma Ltd., is $0.2899 per EA (NDC 72888007201), effective Sep 30, 2026.
How has the price of AMITRIPTYLINE HCL 150 MG TAB changed over time?
Over the history we have for it, the NADAC for AMITRIPTYLINE HCL 150 MG TAB has risen 56.7%. It has been tracked across 82 weekly CMS publications since Mar 12, 2025.
What are the highest and lowest recorded NADAC prices for AMITRIPTYLINE HCL 150 MG TAB?
Since Mar 12, 2025, the NADAC for AMITRIPTYLINE HCL 150 MG TAB has ranged from a low of $0.1849 (Mar 19, 2025) to a high of $0.3070 (Sep 16, 2026), with a median of $0.2831 per EA.
Are there cheaper alternatives to AMITRIPTYLINE HCL 150 MG TAB?
8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as AMITRIPTYLINE HCL 150 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures AMITRIPTYLINE HCL 150 MG TAB?
AMITRIPTYLINE HCL 150 MG TAB (NDC 72888007201) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.